Cancer Cell Metabolism: Implications for X-ray and Particle Radiation Therapy

Sertorio, Mathieu; Perentesis, John P.; Vatner, Ralph; Mascia, Anthony; Zheng, Yi; Wells, Susanne I.

doi:10.14338/ijpt-18-00023.1

Cited by 9 publications

(7 citation statements)

References 60 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The choice of the early time point was made to bypass immediate DNA damage responses. We used human and murine lymphoma cells in order to identify evolutionarily conserved responses to radiation based on a "cross-species filter" 19,20 21 . We next defined a "lymphoma PT irradiation signature" corresponding to 167 genes deregulated in both BL41 and J3D cells after PT but not X-ray irradiation (Fig1C).…”

Section: Resultsmentioning

confidence: 99%

Differential transcriptome response to proton versus X-ray radiation reveals novel candidate targets for combinatorial PT therapy in lymphoma

Sertorio

Nowrouzi²,

Akbarpour³

et al. 2021

Radiotherapy and Oncology

Self Cite

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Resultsmentioning

confidence: 99%

Differential transcriptome response to proton versus X-ray radiation reveals novel candidate targets for combinatorial PT therapy in lymphoma

Sertorio

Nowrouzi²,

Akbarpour³

et al. 2021

Radiotherapy and Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Radiation refers to ionizing radiation, such as X‐ray, γ‐ray, and particle radiation, or electromagnetic radiation, to kill cancer cells and prevent the further spreading of cancer cells. [ 208 ] However, high‐intensity and long‐time radiation induce radio‐dermatitis, which seriously affects the life quality of the patient. Therefore, it is necessary to reduce the intensity of radiation and utilize targeted drug delivery to reduce their distribution in normal tissue for minimal side effects.…”

Section: Exo‐stimuli‐responsive Nanoparticles (Ex‐srnps) For Smart Dr...mentioning

confidence: 99%

Stimuli‐Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer Immunotherapy

Zhang

Lin

Lin³

et al. 2021

Advanced Science

135

View full text Add to dashboard Cite

Cancer immunotherapy has achieved promising clinical progress over the recent years for its potential to treat metastatic tumors and inhibit their recurrences effectively. However, low patient response rates and dose-limiting toxicity remain as major dilemmas for immunotherapy. Stimuli-responsive nanoparticles (srNPs) combined with immunotherapy offer the possibility to amplify anti-tumor immune responses, where the weak acidity, high concentration of glutathione, overexpressions of enzymes, and reactive oxygen species, and external stimuli in tumors act as triggers for controlled drug release. This review highlights the design of srNPs based on tumor microenvironment and/or external stimuli to combine with different anti-tumor drugs, especially the immunoregulatory agents, which eventually realize synergistic immunotherapy of malignant primary or metastatic tumors and acquire a long-term immune memory to prevent tumor recurrence. The authors hope that this review can provide theoretical guidance for the construction and clinical transformation of smart srNPs for controlled drug delivery in synergistic cancer immunotherapy.

show abstract

“…On the other hand, conventional chemotherapy and radiation generate much of their anti-tumorigenic activity by dramatically increasing ROS levels above those which tumor cells can absorb without catastrophic damage to their DNA ( 22 ). The TME is a site of significant interaction between these cancer therapeutics and cancer metabolism, and the TME can promote cancer survival by impairing the efficacy of radiation, chemotherapy, and immunotherapy ( 18 , 23 – 25 ). Since the cytotoxic effects of radiation are potentiated by oxygen, hypoxic tumor stromal regions of the TME can drive radioresistance and local treatment failure ( 18 ).…”

Section: Metabolic Regulation Of Oxidative Stressmentioning

confidence: 99%

“…Since the cytotoxic effects of radiation are potentiated by oxygen, hypoxic tumor stromal regions of the TME can drive radioresistance and local treatment failure ( 18 ). The acidification of the TME promotes cancer cell metabolic reprogramming, selects for cancer cells that are resistant to hypoxic conditions, and therefore promotes chemoresistance and metastatic development ( 25 ). The TME and ROS production present a targetable area for cancer therapeutics that will be discussed further in this review.…”

Section: Metabolic Regulation Of Oxidative Stressmentioning

confidence: 99%

Metabolic targeting, immunotherapy and radiation in locally advanced non-small cell lung cancer: Where do we go from here?

Dhawan

Pifer²,

Sandulache³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

In the US, there are ~250,000 new lung cancer diagnoses and ~130,000 deaths per year, and worldwide there are an estimated 1.6 million deaths per year from this deadly disease. Lung cancer is the most common cause of cancer death worldwide, and it accounts for roughly a quarter of all cancer deaths in the US. Non-small cell lung cancer (NSCLC) represents 80-85% of these cases. Due to an enormous tobacco cessation effort, NSCLC rates in the US are decreasing, and the implementation of lung cancer screening guidelines and other programs have resulted in a higher percentage of patients presenting with potentially curable locoregional disease, instead of distant disease. Exciting developments in molecular targeted therapy and immunotherapy have resulted in dramatic improvement in patients’ survival, in combination with new surgical, pathological, radiographical, and radiation techniques. Concurrent platinum-based doublet chemoradiation therapy followed by immunotherapy has set the benchmark for survival in these patients. However, despite these advances, ~50% of patients diagnosed with locally advanced NSCLC (LA-NSCLC) survive long-term. In patients with local and/or locoregional disease, chemoradiation is a critical component of curative therapy. However, there remains a significant clinical gap in improving the efficacy of this combined therapy, and the development of non-overlapping treatment approaches to improve treatment outcomes is needed. One potential promising avenue of research is targeting cancer metabolism. In this review, we will initially provide a brief general overview of tumor metabolism as it relates to therapeutic targeting. We will then focus on the intersection of metabolism on both oxidative stress and anti-tumor immunity. This will be followed by discussion of both tumor- and patient-specific opportunities for metabolic targeting in NSCLC. We will then conclude with a discussion of additional agents currently in development that may be advantageous to combine with chemo-immuno-radiation in NSCLC.

show abstract

Cancer Cell Metabolism: Implications for X-ray and Particle Radiation Therapy

Cited by 9 publications

References 60 publications

Differential transcriptome response to proton versus X-ray radiation reveals novel candidate targets for combinatorial PT therapy in lymphoma

Differential transcriptome response to proton versus X-ray radiation reveals novel candidate targets for combinatorial PT therapy in lymphoma

Stimuli‐Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer Immunotherapy

Metabolic targeting, immunotherapy and radiation in locally advanced non-small cell lung cancer: Where do we go from here?

Contact Info

Product

Resources

About